Compare iShares JPMorgan USD Emerging Markets Bond ETF (EMB) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares JPMorgan USD Emerging Markets Bond ETF vs 10X Genomics Inc — how do they compare? iShares JPMorgan USD Emerging Markets Bond ETF trades at $91.59 (market cap $12.79B), while 10X Genomics Inc trades at $79.4 (market cap $9.92B). The key difference: iShares JPMorgan USD Emerging Markets Bond ETF is the larger of the two by market cap, and 10X Genomics Inc is trading nearer its 52-week high, iShares JPMorgan USD Emerging Markets Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares JPMorgan USD Emerging Markets Bond ETF for 50 Days and 10X Genomics Inc for 92 Days on average.
| EMB | TXG | |
|---|---|---|
Market Cap | $12.79B | $9.92B |
Volume | 8,552,536 | 9,372,166 |
Sector | Fixed Income | Health |
52-Week High | $97.74 | $97.74 |
52-Week Low | $90.14 | $11.48 |
Typical Hold Time | 50 Days | 92 Days |
Enterprise Value | — | $9.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EMB trades at $90.78, down 0.19% with a bearish technical signal from moving averages. The stock shows mixed momentum with RSI indicators suggesting potential oversold conditions at lower timeframes. Recent corporate actions include scheduled dividend payments through late 2026, though key valuation and profitability metrics remain unavailable for analysis.
The outlook remains cautious with technical indicators favoring bearish momentum. Investment appeal may center on future dividend income given the lack of current fundamental data. Primary risks include market volatility and the absence of transparent financial metrics for proper valuation assessment.
10x Genomics (TXG) trades at $77.28, down 4.19% on the day, amid a bearish technical signal. The company reported revenue of $642.82M in 2025, with a net loss of $43.54M, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights the launch of its Atera spatial biology platform and a patent victory, signaling innovation and market strength. Cash flow from operations improved to $136.05M in 2025, indicating better operational efficiency.
The outlook is cautiously optimistic, with strong product demand and improving margins offering upside potential. However, persistent losses, high valuation multiples, and competitive pressures present significant risks. Analyst consensus is mixed, with a $74.30 price target slightly below the current price, reflecting uncertainty about near-term profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares JPMorgan USD Emerging Markets Bond ETF
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
